pSLQ5465_pHR_hU6-crScaffold_EF1a-PuroR-T2A-BFP Citations (1)

Originally described in: Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS Cell. 2020 May 14;181(4):865-876.e12. doi: 10.1016/j.cell.2020.04.020. Epub 2020 Apr 29. PubMed Journal

---

Articles Citing pSLQ5465_pHR_hU6-crScaffold_EF1a-PuroR-T2A-BFP

Articles

Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. Zeng L, Liu Y, Nguyenla XH, Abbott TR, Han M, Zhu Y, Chemparathy A, Lin X, Chen X, Wang H, Rane DA, Spatz JM, Jain S, Rustagi A, Pinsky B, Zepeda AE, Kadina AP, Walker JA 3rd, Holden K, Temperton N, Cochran JR, Barron AE, Connolly MD, Blish CA, Lewis DB, Stanley SA, La Russa MF, Qi LS. Nat Commun. 2022 May 19;13(1):2766. doi: 10.1038/s41467-022-30546-7. PubMed

If you have published an article using this material, please email us at to have your article added to this page.